MediWound Ltd.
MDWD Healthcare Biotechnology
MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow MDWD
MediWound Ltd. (MDWD) EV/Sales
As of 16 October 2026, MediWound Ltd. (MDWD) trades at a EV/Sales of 10.0×. Over the past ten years it has ranged from 0.4× (April 2020) to 427× (January 2015); the current reading is higher than 58% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 9.3× | 39.60% |
| FY2024 | 6.7× | 101.38% |
| FY2023 | 3.3× | 166.36% |
| FY2022 | 1.2× | (45.18%) |
| FY2021 | 2.3× | (38.11%) |
| FY2020 | 3.7× | 110.14% |
| FY2019 | 1.7× | (93.16%) |
| FY2018 | 25.5× | (9.57%) |
| FY2017 | 28.2× | (48.32%) |
| FY2016 | 54.5× | (76.58%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.1× | 15.56% |
| Mar 2026 | 11.3× | 21.53% |
| Dec 2025 | 9.3× | 38.50% |
| Sep 2025 | 6.7× | (25.18%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NBP NovaBridge Biosciences compare | −3.8× |
| CMPX Compass Therapeutics, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.1× |
| CDXS Codexis, Inc. compare | 1.2× |
| CHRS Coherus Oncology, Inc. compare | 5.1× |
| MDWD MediWound Ltd. | 10.0× |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)